We are live on ! Find out more

NexGel Inc Warrant

NXGLW

Market cap $25.8K

0.0125 USD

0.0000

0%

At close Updated Sep 4, 4:00 PM EDT

Pre-market

After hours

0.0125

0.0000

0%

1 day

0%

5 days

3.31%

1 month

-21.87%

3 months

-67.02%

6 months

-89.6%

Year to date

-94.34%

1 year

-95.69%

5 years

-98.4%

10 years

-98.4%

About: NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.

Employees: 19

Healthcare Medical Instruments & Supplies

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

NEXGEL Reports Second Quarter 2026 Financial Results

LANGHORNE, Pa., Aug. 17, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its second quarter 2026 financial results for the period ending June 30, 2026.

NEXGEL Reports Second Quarter 2026 Financial Results

NEXGEL to Present at Planet MicroCap Conference Las Vegas on June 16th –18th

LANGHORNE, Pa., June 04, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced that Adam Levy, Chief Executive Officer, will present at the Planet MicroCap Conference on June 16 – 18, 2026, in Las Vegas, NV.

NEXGEL to Present at Planet MicroCap Conference Las Vegas on June 16th –18th

NEXGEL Reports Positive Data from Randomized Single-Center IRB Study to Evaluate the Effectiveness and Safety of a Hydrogel Laser Treatment Patch in Laser Hair Removal with a 95.6% Reduction in Plume Concentration

The study concluded that NEXGEL's hydrogel patch significantly reduced laser plume generation and exposure during laser hair removal and the patch was associated with greater hair reduction and reduced pain compared to the control The study was published in Lasers in Surgery and Medicine, 2026 LANGHORNE, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced positive data from the randomized, 30-patient, single-center Institutional Review Board (IRB) clinical study, funded by Innovative Optics, a leading supplier of safety products and personal protective equipment for medical, surgical and aesthetic healthcare facilities globally.

NEXGEL Reports Positive Data from Randomized Single-Center IRB Study to Evaluate the Effectiveness and Safety of a Hydrogel Laser Treatment Patch in Laser Hair Removal with a 95.6% Reduction in Plume Concentration

NEXGEL, Inc. (NXGL) Q1 2026 Earnings Call Transcript

NEXGEL, Inc. (NXGL) Q1 2026 Earnings Call Transcript

NEXGEL, Inc. (NXGL) Q1 2026 Earnings Call Transcript

NEXGEL Appoints Dave Hazard as Vice President of Sales for BIONX Surgical

Appointment Supports Commercialization of Newly Launched BIONX Surgical Division, Formed Through Transformative Acquisition Expected to Significantly Scale Revenue LANGHORNE, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the appointment of Dave Hazard as Vice President of Sales for BIONX Surgical, a division of NEXGEL.

NEXGEL Appoints Dave Hazard as Vice President of Sales for BIONX Surgical

NEXGEL To Report First Quarter 2026 Financial Results on May 15th

Management Will Host a Conference Call at 12:00 P.M. ET on the Same Day LANGHORNE, Pa.

NEXGEL To Report First Quarter 2026 Financial Results on May 15th

NEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience™, to Board of Directors

Sequence LifeScience TM Led Financing to Close on Acquisition of Celularity with Strategic Investment of $5.5 Million LANGHORNE, Pa., May 06, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the appointment of Brian J.

NEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience™, to Board of Directors

NEXGEL, Inc. (NXGL) Q4 2025 Earnings Call Transcript

NEXGEL, Inc. (NXGL) Q4 2025 Earnings Call Transcript

NEXGEL, Inc. (NXGL) Q4 2025 Earnings Call Transcript

See News Rankings

Price charts implemented using Lightweight Charts™